Medco, Abbott and Fujisawa tie up loose ends:
This article was originally published in Clinica
Medco Research and Abbott Laboratories have terminated their manufacturing and marketing agreements regarding Medco's newly-approved Adenoscan (adenosine injection) coronary vasodilator for thallium imaging (see Clinica No 656, p 18). The decision follows Medco and Fujisawa's (Japan) recent litigation settlement under which Fujisawa retains the manufacturing and marketing rights to Adenoscan in North America (see Clinica No 656, p 18). At the three companies' request, the US District Court for Northern Illinois dismissed their pending claims with prejudice. Other details of the termination agreement were not disclosed.